Editas Medicine Inc. (EDIT)
EDIT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.44
-11.09% on the day
Market cap
$375.5M
Small cap
Revenue · 2025
$40.5M
+25.4% on 2024
Net income · 2025
-$160.1M
-395.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | EDIT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001650664 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $40.5M |
| Net income | -$160.1M |
| Operating income | -$160.0M |
| Net margin | -395.0% |
| Operating margin | -394.9% |
| Revenue growth | +25.4% |
| Cash | $146.6M |
| Total assets | $186.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-31 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-10-08 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 726 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.9% |
| 1 month | -14.1% |
| 3 months | -21.6% |
| Year to date | +10.2% |
| 1 year | -36.5% |
| From 52-week high | -45.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TRXB | TRex Bio Inc. | $13.60 | -3.06% | $373.3M |
| EIKN | Eikon Therapeutics Inc. | $6.72 | -7.44% | $364.0M |
| SCTX | Scribe Therapeutics Inc. | $19.12 | -7.50% | $362.0M |
| KYTX | Kyverna Therapeutics Inc. | $5.77 | -7.08% | $356.8M |
| FENC | Fennec Pharmaceuticals Inc. | $10.18 | -5.04% | $356.6M |
| ZURA | Zura Bio Limited | $4.23 | +5.75% | $405.4M |
| CCCC | C4 Therapeutics Inc. | $2.78 | -9.15% | $342.0M |
| TECX | Tectonic Therapeutic Inc. | $21.31 | -4.65% | $416.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier